We demonstrated in the current study that patients of IDH1 mutation concurrent with tumor-SVZ distance >10 mm have the best clinical outcome compared with patients bearing wild-type IDH1 and tumor-SVZ distance <10 mm, which exhibit the poorest survival time and shorter tumor relapse. The gene discussed is IDH1; the disease is neoplasm.